Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
Journal article published in 2018 by
C. Cremolini 
,
C. Antoniotti,
S. Lonardi,
F. Bergamo,
E. Cortesi,
G. Tomasello,
R. Moretto,
M. Ronzoni,
P. Racca,
F. Loupakis,
A. Zaniboni,
G. Tonini,
A. Buonadonna,
F. Marmorino,
G. Allegrini
and other authors.
,
C. Antoniotti,
S. Lonardi,
F. Bergamo,
E. Cortesi,
G. Tomasello,
R. Moretto,
M. Ronzoni,
P. Racca,
F. Loupakis,
A. Zaniboni,
G. Tonini,
A. Buonadonna,
F. Marmorino,
G. Allegrini
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 